Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 ...

Lofty expectations for continuing sales of vaccines and antivirals have fallen short, sending Pfizer's stock price tumbling ...

Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer and BioNTech may have a strong pedigree in the mRNA vaccine game, but, when it comes to flu, they’ve run up against ...

A combination Covid-flu vaccination developed by Pfizer Inc. and BioNTech SE missed on one of its goals in a final-stage ...

Germany's BioNTech and US pharma giant Pfizer said Friday they had suffered a setback in a late-stage trial of their combined ...

Pfizer and BioNTech said Friday that a Phase 3 trial of their COVID-19-and-influenza combination vaccine candidate met one of ...

Pfizer and BioNTech’s Covid-19 and flu vaccine failed to meet a key goal in a late-stage trial, jeopardising a highly ...

Opinions expressed by Forbes Contributors are their own. We provide aggregated data on dividend stocks. In trading on Friday, ...

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity ...

Investors were cautiously pessimistic about the latest news coming out of the company's lab. Before market open, Pfizer and ...